Sonoma Pharmaceuticals authorizes $3.6M at-market equity offering

Sonoma Pharmaceuticals received legal counsel opinion for a proposed $3.6 million common stock offering under an at-market issuance agreement with Ladenburg Thalmann. The offering provides the company with capital raising flexibility through its existing Form S-3 registration statement.